NBIX Stock Neurocrine Biosciences (NBIX, $151.58) was a top weekly gainer, with a +9.79% jump

GET DAILY SIGNALS

Get AI intraday signals

NBIX - Neurocrine Biosciences

Loading...

Price: $151.58

Daily change: +$8.05 (+5.61%)

Daily volume: 1.7M

Weekly price change: +$13.52 (+9.79%)

Capitalization: $15.1B

Industry: Pharmaceuticals: Generic

Neurocrine Biosciences (NBIX, $151.58) was one of the top gainers this week, climbing to $151.58 per share. A.I.dvisor analyzed 215 stocks in the Pharmaceuticals: Generic Industry over the last week and discovered that of them (8) trended up while of them (1) trended down.

NBIX in +2.15% Uptrend, advancing for three consecutive days on February 03, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NBIX advanced for three days, in of 306 cases, the price rose further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NBIX's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on January 27, 2026. You may want to consider a long position or call options on NBIX as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NBIX just turned positive on January 22, 2026. Looking at past instances where NBIX's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

NBIX moved below its 50-day moving average on December 26, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NBIX crossed bearishly below the 50-day moving average on December 29, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NBIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NBIX entered a downward trend on January 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NBIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.613) is normal, around the industry mean (29.792). P/E Ratio (33.169) is within average values for comparable stocks, (74.095). Projected Growth (PEG Ratio) (0.360) is also within normal values, averaging (2.035). NBIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (5.294) is also within normal values, averaging (116.680).